An essay presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) suggests that new age of obesity drugs could shift the blame for living with obesity from individuals to ...
The Food and Drug Administration has approved the second GLP-1 pill to treat obesity, this time from drugmaker Eli Lilly. The new pill, Foundayo, is taken once a day and will compete with the ...
Eli Lilly wants to get its obesity drugs into the hands of more Americans and it’s betting on employers to help do so. The Indianapolis-based drugmaker launched a new program on Thursday that’s ...
Feb 18 (Reuters) - Global food and beverage companies from PepsiCo to Coca-Cola are focusing on shorter ingredient lists and smaller pack sizes in 2026 as more people take appetite-suppressing ...
Before the rise of GLP-1s, obesity experts didn’t study the internal buzz that compels people to eat. Now that food noise is being switched off, they want to understand it. Credit...Xia Gordon ...
Scientists developed a five-target obesity drug that outperformed Ozempic in weight loss and blood sugar control in obese ...
Hosted on MSN
Lilly surges on fast-tracked obesity pill approval
Eli Lilly’s shares jumped after the FDA approved its once‑daily oral obesity drug Foundayo, fast‑tracked under a new review program. The pill offers greater convenience than rival Novo Nordisk’s ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novo Nordisk ...
Novo Nordisk and Eli Lilly still have first-mover advantage, but Roche, Pfizer and others all have similar products in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results